Skip to content
Medical Health Aged Care

Australian PrEP supply constraints to begin easing

Health Equity Matters < 1 mins read

 

Supplies of the HIV prevention medicine, PrEP, will begin to return to normal, with the Therapeutic Goods Administration and the Pharmaceutical Benefits Scheme listing a new manufacturer, Laurus Labs to help overcome a shortage.

Supply constraints will start to ease imminently, and it is anticipated the shortage will be resolved by early November after being constrained for the last six weeks. 

 

 

James Gray, Principal Director, Australia Program at Health Equity Matters, the peak body for communities affected by HIV, said: "It is expected PrEP will soon return to normal availability. If you have enough supply to cover you for the next few weeks, we ask you to hold off on sourcing more PrEP through pharmacies unless you are travelling overseas or live in a remote community. We also ask people to purchase only one bottle of PrEP (that is, 30 pills) at a time until the resumption of full supply and, likewise, pharmacists to only dispense one bottle at a time."

 

ASHM CEO Alexis Apostolellis said: "Doctors providing PrEP scripts should ask patients to hold off filling scripts until late October unless they are travelling, live in remote areas or are in immediate need of medication."

 

Another option for individuals who need PrEP is to import the medication through websites such as PrEPaccessNow. Additionally, there are several ways to take PrEP safely, including on-demand and periodic use, which involve reduced medication consumption. Community members are urged to discuss these options with their GP and consult health promotion websites like Emen8 to learn more about alternative ways to take PrEP.

 

 

To arrange an interview, call Nick Lucchinelli 0422229032

More from this category

  • Disability, Medical Health Aged Care
  • 20/12/2024
  • 17:36
Kuremara

Kuremara to Open a State-of-the-Art Activity Center in Milton, QLD, in January 2025

Kuremara, a trusted and leading NDIS-registered provider in Australia, is excited to announce the opening of its newest facility—a cutting-edge activity center in Milton,…

  • Contains:
  • Legal, Medical Health Aged Care
  • 20/12/2024
  • 17:29
JGA Saddler

BREAKING NEWS: Australian law firm takes on Johnson & Johnson for selling Australians ineffective medicine

Vision available: Lawyer and doctor VNR, editorial photos and radio grabs included can be found in this SharePoint File In-person lawyer interviews available by…

  • Contains:
  • Medical Health Aged Care
  • 20/12/2024
  • 12:01
NDARC/UNSW

ADHD drug shows promise for treating methamphetamine dependence, landmark Australian study shows

A prescription medication used to treat attention deficit hyperactivity disorder (ADHD) could be repurposed as the first pharmacotherapy for people with methamphetamine dependence, according to a study published in Addiction. Results from the landmark ‘LiMA’ trial show that thepsychostimulant lisdexamfetamine can drastically reduce the need to use methamphetamine among those who are dependent on the illicit drug. Lead author and addiction medicine specialist Professor Nadine Ezard, who is Director of the National Centre for Clinical Research on Emerging Drugs (NCCRED), said the results were promising. "There is currently no pharmacotherapy approved for treating methamphetamine dependence," Professor Ezard said. “While further…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.